PTC Therapeutics, Inc.

539 articles with PTC Therapeutics, Inc.

• Judge Rules PTC Therapeutics, Inc. Must Give Experimental Drug to Teen

  8/21/2008

• PTC Therapeutics, Inc. (JOBS) Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics, Inc. for Development of PTC124

  7/16/2008

• PTC Therapeutics, Inc. Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity

  6/12/2008

• PTC Therapeutics, Inc. PTC124 Featured at Third Annual Congress of Myology - PTC Announces Initiation of Additional Phase 2b Clinical Trial Sites in Europe

  5/30/2008

• PTC Therapeutics, Inc. Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis

  5/21/2008

• PTC Therapeutics, Inc. Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy

  4/23/2008

• PTC Therapeutics, Inc. Announces Publication of Preclinical Data in PNAS

  2/5/2008

• PTC Therapeutics, Inc. Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium

  12/17/2007

• PTC Therapeutics, Inc. Announces Additional $1.6 Million Grant from the Spinal Muscular Atrophy Foundation

  12/6/2007

• PTC Therapeutics, Inc. Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy Data Presented at the World Muscle Society International Congress

  10/18/2007

• PTC Therapeutics, Inc. Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy

  10/12/2007

• PTC Therapeutics, Inc. Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis

  10/5/2007

• PTC Therapeutics, Inc. (Jobs) Announces $20 Million Strategic Investment From Celgene (Jobs)

  9/13/2007

• PTC Therapeutics, Inc. Appoints Theresa Natalicchio as Senior Vice President of Marketing and Sales

  8/2/2007

• PTC Therapeutics, Inc. Announces $15.4 Million National Institutes of Health (NIH) Research Grant for Duchenne Muscular Dystrophy

  7/10/2007

• PTC Therapeutics, Inc. Appoints Manal Morsy, M.D., PH.D. as Vice President of Regulatory Affairs

  6/26/2007

• PTC Therapeutics, Inc. Presents Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 43rd American Society of Clinical Oncology Annual Meeting

  6/4/2007

• PTC Therapeutics, Inc. (Jobs) Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy

  5/4/2007

• PTC Therapeutics, Inc. Announces Promotion of Neil Almstead to Senior Vice President of Chemistry and CMC

  5/2/2007

• PTC Therapeutics, Inc. Announces Strategic Drug Discovery Collaboration With Pfizer Inc. Utilizing PTC's GEMS Technology Platform

  1/8/2007